• news.cision.com/
  • Xvivo Perfusion/
  • As a result of Covid-19: The Annual General Meeting of XVIVO Perfusion is moved to a new address and further precautions are taken

As a result of Covid-19: The Annual General Meeting of XVIVO Perfusion is moved to a new address and further precautions are taken

Report this content

As a precautionary measure to reduce the risk of spreading the new corona virus (Covid-19), the Board of Directors of XVIVO Perfusion AB has decided to move the Annual General Meeting to larger premises at the Svenska Mässan (conference room J1) at Mässans gata 24 in Gothenburg. The date and time for the Annual General Meeting will is still Tuesday, March 31 at. 15:00.

In order to safeguard the participants' health, a further number of decisions have been made regarding the implementation of the company's annual general meeting. The goal is for the AGM to be short and effective to minimize the risk of spreading covid-19.

The following changes have been decided:

  • The AGM moves to larger premises
  • The participation of both board members and employees will be limited.
  • The CEO's speech is canceled. Instead, a pre-recorded video presentation will be available on the company's website (www.xvivoperfusion.com) after the closing of the AGM.
  • No ingestion or beverages will be offered in conjunction with the AGM.

​​​​​Fewer participants, greater distances, shorter time and less interaction are all considered to contribute to a significantly reduced risk of transmission.

Shareholders who are ill, have recently resided in a risk area or belong to a risk group should not participate, but can vote via proxy. A proxy form is available on the company's website www.xvivoperfusion.com. Kristoffer Nordström, Group Accounting Manager at XVIVO Perfusion AB (publ), can advantageously be used as a representative and can be contacted at telephone number +46 735 192164 or by e-mail at kristoffer.nordstrom@xvivperfusion.com. The last day for registration is March 26, in accordance with what was previously communicated


March 18, 2020
XVIVO Perfusion AB (publ)

For further information please contact:
Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31-788 21 50, e-post: magnus.nilsson@xvivoperfusion


This information is information that XVIVO Perfusion AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication on March 18, 2020 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com